We can’t show the full text here under this license. Use the link below to read it at the source.
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)
Comparing canagliflozin, other SGLT2 inhibitors, and non-SGLT2 drugs for heart failure hospitalizations and amputations in type 2 diabetes patients
AI simplified
Abstract
The hazard ratio estimate for with canagliflozin vs non-SGLT2i was 0.39.
- Canagliflozin is associated with a significantly lower risk of hospitalization for heart failure compared to non-SGLT2i.
- The hazard ratio for below-knee lower extremity amputation with canagliflozin vs non-SGLT2i was 0.75 in the on-treatment analysis, but 1.01 in the intent-to-treat analysis.
- Similar effects for hospitalization for heart failure and below-knee lower extremity amputation were observed in patients with established cardiovascular disease.
- No consistent differences were noted between canagliflozin and other SGLT2i regarding these outcomes.
AI simplified
Key numbers
0.39
Decrease in Risk
Meta-analytic hazard ratio for with canagliflozin vs non-SGLT2i
0.75
Amputation Risk
Meta-analytic hazard ratio for amputation with canagliflozin vs non-SGLT2i
142800
New Users of Canagliflozin
Total number of new users of canagliflozin across 4 databases